Abstract
Extensive evidence supports involvement of electron transfer (ET), reactive oxygen species (ROS) and oxidative stress (OS) in the mechanism of many anticancer drugs. The common ET functionalities, usually present in the drug metabolites, are quinones (or precursors), metal complexes (or complexors), hydroxylamine and nitroso from ArNO2 or ArNH2, and conjugated imines (or iminium species). The ET agents function catalytically in redox cycling with formation of ROS from oxygen. Electrochemical data add support to the mechanistic viewpoint. The generated metabolites generally possess reduction potentials amenable to ET in vivo, thus giving rise to ROS. The resulting OS is a participant in destruction of the cancer cell. The action has been termed phagomimetic based on similarity to phagocytosis. It is important to recognize that drug action is often multipronged. The various modes of action are summarized.
Keywords: Anticancer, electron transfer, reactive oxygen species, oxidative stress, ArNO2 or ArNH2, physiological responsive range, exogenous AOs, chemotherapy, mutagenic effects, transformation
Anti-Cancer Agents in Medicinal Chemistry
Title: Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Volume: 11 Issue: 7
Author(s): Peter Kovacic and Ratnasamy Somanathan
Affiliation:
Keywords: Anticancer, electron transfer, reactive oxygen species, oxidative stress, ArNO2 or ArNH2, physiological responsive range, exogenous AOs, chemotherapy, mutagenic effects, transformation
Abstract: Extensive evidence supports involvement of electron transfer (ET), reactive oxygen species (ROS) and oxidative stress (OS) in the mechanism of many anticancer drugs. The common ET functionalities, usually present in the drug metabolites, are quinones (or precursors), metal complexes (or complexors), hydroxylamine and nitroso from ArNO2 or ArNH2, and conjugated imines (or iminium species). The ET agents function catalytically in redox cycling with formation of ROS from oxygen. Electrochemical data add support to the mechanistic viewpoint. The generated metabolites generally possess reduction potentials amenable to ET in vivo, thus giving rise to ROS. The resulting OS is a participant in destruction of the cancer cell. The action has been termed phagomimetic based on similarity to phagocytosis. It is important to recognize that drug action is often multipronged. The various modes of action are summarized.
Export Options
About this article
Cite this article as:
Kovacic Peter and Somanathan Ratnasamy, Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/187152011796817691
DOI https://dx.doi.org/10.2174/187152011796817691 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Anti-Tumor Vaccines in Head and Neck Cancer: Targeting Immune Responses to the Tumor
Current Cancer Drug Targets A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties
Current Molecular Medicine Update on Statins: Hope for Osteoporotic Fracture Healing Treatment
Current Drug Targets Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Probiotic Multistrain Treatment May Eradicate Helicobacter pylori from the Stomach of Dyspeptics: A Placebo-Controlled Pilot Study
Inflammation & Allergy - Drug Targets (Discontinued) NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Orthotopic Liver Transplantation in Non-Alcoholic Fatty Liver Disease Patients
Reviews on Recent Clinical Trials The Association of Chemotherapy and Radiotherapy: Breast Cancer
Current Drug Therapy Clonetics
Current Drug Metabolism Prophylactic Potential of Conventional and Supercritical Garlic Extracts to Alleviate Diet Related Malfunctions
Recent Patents on Food, Nutrition & Agriculture Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Current Drug Targets Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Recombinant Snake Venom Cystatin Inhibits Tumor Angiogenesis in vitro and in vivo Associated with Downregulation of VEGF-A165, Flt-1 and bFGF
Anti-Cancer Agents in Medicinal Chemistry Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern
Current Drug Safety Regulation of MicroRNAs by Phytochemicals: A Promising Strategy for Cancer Chemoprevention
Current Cancer Drug Targets Metabolic Homeostasis and Colonic Health: the Critical Role of Short Chain Fatty Acids
Current Nutrition & Food Science Helicobacter Pylori and Inflammation
Current Pharmaceutical Design